Back to mobile site

Exelixis' (EXEL) Zanzalintinib Centerpiece of Near-term Strategy - Stifel

December 11, 2025 7:42 AM EST Send to a Friend
Stifel analyst Stephen Willey reiterated a Hold rating and $43.00 price target on Exelixis (NASDAQ: EXEL).The analyst commented, "Exelixis’s R&D ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login